Joseph A. Fraietta, Ph.D.
Affiliations: | 2012 | Drexel University College of Medicine, Philadelphia, PA, United States |
Area:
HIV, CD8 T cellGoogle:
"Joseph Fraietta"Mean distance: 20037.4
Parents
Sign in to add mentor| Peter D. Katsikis | grad student | 2012 | Drexel Medical School | |
| (Targeting Inflammation for the Prevention of Human Immunodeficiency Virus (HIV) Transmission and Disease Progression.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Jadlowsky JK, Hexner EO, Marshall A, et al. (2025) Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies. Nature Medicine |
| Chong EA, Penuel E, Napier EB, et al. (2024) Impact of prior CAR-T cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas. Blood Advances |
| Dimitri AJ, Baxter AE, Chen GM, et al. (2024) TET2 regulates early and late transitions in exhausted CD8 T cell differentiation and limits CAR T cell function. Science Advances. 10: eadp9371 |
| Bhagwat AS, Torres L, Shestova O, et al. (2024) Cytokine-mediated CAR T therapy resistance in AML. Nature Medicine |
| Chang JF, Wellhausen N, Engel NW, et al. (2024) Identification of core techniques that enhance genome editing of human T cells expressing synthetic antigen receptors. Cancer Immunology Research |
| Fuller AM, Pruitt HC, Liu Y, et al. (2024) Oncogene-induced matrix reorganization controls CD8+ T cell function in the soft-tissue sarcoma microenvironment. The Journal of Clinical Investigation |
| Doan AE, Mueller KP, Chen AY, et al. (2024) FOXO1 is a master regulator of memory programming in CAR T cells. Nature |
| Chong EA, Chong ER, Therwhangher D, et al. (2024) Bendamustine as lymphodepletion for brexucabtagene autoleucel therapy of mantle cell lymphoma. Transplantation and Cellular Therapy |
| Myers RM, Devine KJ, Li Y, et al. (2024) Reinfusion of CD19 CAR T Cells for Relapse Prevention and Treatment in Children with Acute Lymphoblastic Leukemia. Blood Advances |
| Ghilardi G, Fraietta JA, Gerson JN, et al. (2024) T-cell Lymphoma and Secondary Primary Malignancy Risk After Commercial CAR T-cell Therapy. Nature Medicine |